Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Mohamad Mohty and Fabio Ciceri.
Mohamad Mohty
Connection Strength
1.686
Fabio Ciceri
  1. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021 03; 56(3):532-535.
    View in: PubMed
    Score: 0.222
  2. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. Bone Marrow Transplant. 2018 04; 53(4):431-437.
    View in: PubMed
    Score: 0.188
  3. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017 Apr 25; 1(11):669-680.
    View in: PubMed
    Score: 0.178
  4. Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol. 2019 Oct; 98(10):2389-2398.
    View in: PubMed
    Score: 0.052
  5. Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. Bone Marrow Transplant. 2019 12; 54(12):1987-1994.
    View in: PubMed
    Score: 0.052
  6. Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2019 May; 54(5):784.
    View in: PubMed
    Score: 0.051
  7. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2019 09; 54(9):1499-1510.
    View in: PubMed
    Score: 0.050
  8. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018 10; 93(10):1236-1244.
    View in: PubMed
    Score: 0.049
  9. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018 08 28; 2(16):2127-2135.
    View in: PubMed
    Score: 0.049
  10. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2018 11; 183(3):411-420.
    View in: PubMed
    Score: 0.049
  11. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019 04; 54(4):519-530.
    View in: PubMed
    Score: 0.049
  12. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2019 01; 33(1):230-239.
    View in: PubMed
    Score: 0.048
  13. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transplant. 2018 07; 24(7):1406-1414.
    View in: PubMed
    Score: 0.048
  14. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 04 16; 11(1):55.
    View in: PubMed
    Score: 0.048
  15. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018 06; 93(6):769-777.
    View in: PubMed
    Score: 0.048
  16. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018 Jun; 93(6):736-744.
    View in: PubMed
    Score: 0.048
  17. T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). Cancer. 2018 05 15; 124(10):2142-2150.
    View in: PubMed
    Score: 0.047
  18. Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer. 2018 04 01; 124(7):1428-1437.
    View in: PubMed
    Score: 0.047
  19. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018 05; 53(5):521-534.
    View in: PubMed
    Score: 0.047
  20. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018 04; 53(4):422-430.
    View in: PubMed
    Score: 0.047
  21. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018 02; 93(2):246-253.
    View in: PubMed
    Score: 0.047
  22. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017 11; 102(11):1810-1822.
    View in: PubMed
    Score: 0.046
  23. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. Am J Hematol. 2017 Aug; 92(8):789-796.
    View in: PubMed
    Score: 0.045
  24. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2017 Jul 15; 123(14):2671-2679.
    View in: PubMed
    Score: 0.044
  25. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017 06; 102(6):1066-1074.
    View in: PubMed
    Score: 0.044
  26. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017 Feb 28; 1(7):477-485.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.